Foundation for Innovative New Diagnostics Find

“Individuals employed by find are not us residents or us employees. Information pertaining to the number of employees and employee compensation is provided using the best information available from equivalent w-2 & w-3 forms for the various countries in which find employs individuals.”

“The telephone number of the person who possesses the books and records is +41 (22) 710 0590”

“The form 990 is prepared by an independent accounting firm and reviewed by the director of finance. Once approved by the director of finance, the form 990 is also reviewed by the ceo. Additionally, in 2021, find participated in a benchmarking exercise with peer of finance, the form 990 is also reviewed by the ceo. Additionally, in 2021, find participated in a benchmarking exercise with peer organization to ensure consistency of treatment of various items on form 990.”

“Finds conflict of interest policy requires directors, officers and key employees, all other staff members, board members, consultants and partners to disclose actual or potential conflicts of interest when they arise. The person or company is also required to recuse themselves from any decision making.”

“A review by an independent consultant of the ceo's remuneration package was done by the board and forms the basis of a written employment contract. Remuneration terms for officers and key employees are based on market rates for similar positions in specific locations. The compensation committee. This benchmarking is done against an independent report which presents data collected for similar organizations and this exercise is done every 3 years. Salaries for all staff are available to the board and compensation committee. However, the salaries of the c-suite and other key staff are approved by the compensation committee.”

“A review by an independent consultant of the ceo's remuneration package was done by the board and forms the basis of a written employment contract. Remuneration terms for officers and key employees are based on market rates for similar positions in specific locations. The compensation committee. This benchmarking is done against an independent report which presents data collected for similar organizations and this exercise is done every 3 years. Salaries for all staff are available to the board and compensation committee. However, the salaries of the c-suite and other key staff are approved by the compensation committee.”

“Upon request find's governing documents (statutes and by-laws) conflict of interest policy and financial statements are available for inspection at find's offices in geneva, switzerland.”

“(EXPENSES $25,480,451 INCLUDING GRANTS OF $13,087,039)(REVENUE $0) In 2023, FIND made significant progress in projects aimed at improving global health through diagnostics. Achievements include advancements in true point-of-care diagnostic solutions, digital solutions, sequencing, and redistribution of manufacturing capacity over the works. One notable initiative was supporting the development of near-point-of-care and true point-of-care solutions for Covid-19. We collaborated with manufacturers on multi disease platforms and multiplex assays to decentralize diagnostics in LMICs, increasing access to quality testing in the least developed countries. In 2023, a significant project was undertaken to develop and evaluate methods for digitally-enabled integrated screening at the community level in Rwanda and Kenya. This initiative successfully demonstrated the feasibility of decentralizing community-level screening through digital tools, integrating disease screening into community-level digital platforms, and enhancing contact tracing modules for tuberculosis in Rwanda. Another significant achievement was leveraging data in all FIND's activities to become a data innovator in the diagnostics space. This involved making FIND a data-driven organization, implementing the DxConnect data portal to make diagnostics knowledge accessible globally, and integrating data governance into all business processes. This project induced a cultural shift within the organization, positioning FIND as a key player in global health data collaboratives. FIND also focused on transforming the diagnosis and treatment of drug-resistant TB (DR-TB) by accelerating the introduction and global adoption of targeted next-generation sequencing (NGS). Evidences generated by FIND through multi-country clinical evaluations of NGS solutions for the diagnosis of drug-resistant TB provided pivotal evidence for a WHO policy review and subsequently, WHO issued a rapid communication on the use of targeted NGS for the diagnosis of drug-resistant TB in July 2023. In the realm of COVID-19, FIND supported access to COVID-19 antigen rapid diagnostic tests (AgRDTs) in resource-limited countries. This involved partnerships with various manufacturers to develop, optimize, and evaluate high-quality AgRDTs, increase manufacturing capacity, and foster regional production through technology transfer. The project also focused on building regional manufacturing capacity for RDT tests, with an initial focus on HIV tests. FIND also aimed to develop low-cost self-tests and screening technologies to facilitate decentralized testing in healthcare facilities and at home. This initiative supported the registration of self-testing solutions in low- and middle-income countries (LMICs) and provided technology transfer and funding support to ensure rapid availability of these technologies. In addition to these projects, FIND's efforts in 2023 included the development of a yellow fever antigen rapid diagnostic test (RDT) and evidence generation for novel point-of-care (POC) molecular and antigen tests for mpox. These projects collectively contributed to advancing diagnostics, improving access to essential tests, and strengthening health systems in various regions.”

“(EXPENSES $17,309,907 INCLUDING GRANTS OF $6,870,781)(REVENUE $0) In 2023, FIND Access department executed several major initiatives across multiple regions. In Bihar, India, the LSS project provided technical assistance to strengthen laboratory systems, working closely with the government to implement IPHL guidelines and Essential Diagnosis List standards. Success hinged on strong government engagement and continuous on-site mentoring. The Essential Diagnostics Lists (EDL) program achieved significant progress in eight countries. FIND successfully supported NEDL development in Ethiopia, Gambia, Kenya, Malawi, and Vietnam, while work continues in Burkina Faso, Cameroun, and Sao Tome e Principe. In collaboration with ASLM, they published comprehensive guidance for NEDL development and implementation and evaluated factors influencing diagnostics selection and use in 55 African Union member states. FIND also collaborated with McGill University and the Bill & Melinda Gates Foundations Exemplars in Global Health team to generate evidence on exemplars in diagnostics and innovative solutions in diagnostics. This collaboration highlighted the best practices, fostered innovation, and set benchmarks for improving accuracy and efficiency in medical diagnostics. The Diagnostic Network Optimization (DNO) initiative expanded its impact through OptiDx, an advanced analytical tool designed to optimize diagnostic networks for TB, HIV, and other diseases in low and middle-income countries. This program has been particularly impactful in India, where implementation spans 52 districts across 10 states, focusing on universal DST scale-up and improved testing efficiency. FIND's DNO team also launched the DxGeoMap which is a user-friendly, online GIS application designed to map population accessibility to diagnostics with minimal data inputs. The DxGeoMap software helps users by estimating the potential impact of new diagnostic solutions and demonstrating the potential effectiveness of existing diagnostic system thus guiding how interventions may be strengthened. In Indonesia, FIND established a landmark partnership with the Ministry of Health, targeting the enhancement of 18,000 primary health centers. This comprehensive initiative encompasses essential diagnostics access, health workforce capacity building, pandemic surveillance improvement, and the advancement of local diagnostics manufacturing capabilities. The project also includes the development of Indonesia's first National Laboratory Strategic Plan. The ACTA Indo-Pacific Regional Project represents a collaborative effort across Cambodia, PNG, Laos PDR, and Indonesia. Working through a consortium of Australian institutes and CHAI, this initiative established the Regional Public Health Learning Network (RPHLN) and delivers tailored healthcare solutions in partnership with national governments. FIND made significant progress in accelerating Access to COVID-19 solutions by enhancing the accessibility and utilization of self-testing in LMICs. By evaluating commercially available self-tests and conducting comprehensive values and preferences surveys, FIND demonstrated that the public could effectively and satisfactorily use self-tests, which emerged as the preferred mode of testing. Market readiness evaluations were conducted to ensure that the self-tests were suitable for widespread use and could be effectively integrated into existing health systems. Evidence was generated and became crucial in supporting the development of WHO and national policies on self-testing, as well as in driving demand generation efforts to ensure broader adoption and implementation of self-testing practices. Through the objective of the COVID-19 ACTA Management R&D project, FIND has stimulated R&D to generate new innovative tests that enabled access to molecular testing at point of care. The project also monitored the COVID-19 test landscape, maintaining an up-to-date test directory that facilitated the introduction o”

“(EXPENSES $8,701,980 INCLUDING GRANTS OF $2,948,582)(REVENUE $0) To support policy for POC TB, MDR-TB tests and expanded TB testing in PLHIV, FIND conducted clinical evaluation of the impact of using the Molbio Truenat MTB platform/assays in the most peripheral level of healthcare. In addition, evaluated the Cepheid Xpert MTB/XDR 10-colour reflex assay for better diagnosis and quicker initiation of treatment for patients with different types of drug resistance. Also, ran clinical evaluation of an expanded TB diagnostic testing strategy for people living with HIV (PLHIV) using Ultra on sputum, stool and urine, and Abbott Determine TB LAM Ag test on urine, regardless of presence of TB symptoms. FIND's TPP project works in collaboration with WHO, provided a novel framework to guide the future development of TPPs for diagnostics, with an approach that balances accessibility and test performance for TB. FIND developed an impact model that considered access, cost and accuracy to guide performance targets. This work will yield new point-of-care (POC) tests for TB that provide results to the patient during the same clinical visit. This strongly supports the ongoing efforts to bring TB tests and results closer to patients, to enhance overall population-level health. To address the urgent need for a rapid biomarker-based, non-sputum-based test to detect all forms of TB for individuals of all ages, including children; FIND evaluated the Mycobacterium tuberculosis cell free DNA (Mtb-cfDNA) as a biomarker for TB detection. FIND study demonstrated improved analytical sensitivity of WATSON by targeting more loci, developed an improved primer design algorithm, and streamlined the protocol to minimize contamination, enable a more error-free workflow, and facilitate high-throughput evaluation of primers. FIND conducted performance evaluation of the Molbio Diagnostics Truenat MTB Plus/COVID-19 for TB and COVID-19 and NCD screening case detection using prospectively collected NP swabs and sputum samples from participants with symptoms suggestive of TB. The project was implemented in close collaboration with the boda-boda community, creating a high demand for community-based testing services. The digital tool captured complete data for more than 95% of participants and guided the selection of patients for TB and COVID 19 testing, including confirmatory PCR testing. The project allowed the piloting of integration models for other disease programmes, trained healthcare workers and other Ag RDT users, contributed to increased demand for testing, strengthened COVID-19 surveillance and infection prevention and control, and supported the management of Ag RDT supplies. The Unitaid-funded DriveDx4TB project aims to accelerate the introduction of TB diagnostics, after a thorough evaluation and review by internal and external experts, 11 products from 10 manufacturers were selected following an RFP and due diligence process, which was approved by Unitaid in April 2023. The completion of the values and preferences (V&P) study was a significant achievement for the year, assessing end-user preferences in South Africa, Viet Nam, and India for novel sample types, urine and tongue swabs. The study's findings provided essential insights into potential product reception and implementation considerations, with plans for further dissemination (including publications) expected in 2024. Additionally, FIND successfully developed a go-to-market framework including 6 consequential modules during the reporting period. To inform access terms and pricing, FIND initiated an independent cost of goods (COGs) analysis and willingness-to-pay analysis for the public and private sector buyers across all three product classes. Access terms and definitions were co-created by FIND and Unitaid and were included in the initial contracts sent to manufacturers; this process will be revisited during later stage-gates within the project. Lastly, DriveDx4TB actively participated in global an”

“(Expenses $ 30,536,891 including grants of $ 12,922,801)(Revenue $ 0) Antimicrobial Resistance (EXPENSES $5,623,858) AADAUC: Assessment AMR Dx and Abx in-country AMR CARBX Accelerator AMR Dx Accelerator AMR Molecular Assay AMR Neonatal Sepsis South Africa AMR Programme management AMR Score Card AMR STI WP2 Clinical Trial Site Development AMR Strategy AMR Surveillance digital toolkit - Kenya and Nepal COVID-19 Genomic surveillance CRP demonstration studies Cumulative Antibiograms EU ValueDx GoNoGo: Stewardship of new Gonorrhoea antibiotics HAMRAS: HAI surveillance and AMS Improve AMS practices at PHC: POC and digital NEOAMR: Neonatal Sepsis Diagnostic AMR Prevention Rapid Dual LFA for GN and CT Simplified Blood Culture WHO - FIND AMR In country WHO AMR Secondment Complex Humanitarian Environments (EXPENSES $273,112) Conflict Affected Settings Laboratory Strengthenin Partnership Building Hepatitis and HIV (EXPENSES $28,603) Global Policy HCV self-test Impact (EXPENSES $1,487,563) GAP Impact Network Impact general management Impact Information Foundational Value of Diagnostics Malaria and Fever (EXPENSES $3,638,444) Data from RDT lot-testing at time of procurement Dengue evaluation study Diagnosis for UHC Tracker Digital ETAT Evidence for non-invasive malaria tests Evidence Severity Field evaluation of a POC hematology platform FIND-GAVI collaboration FIND-GAVI collaboration (landscaping activities) FIND-GAVI collaboration (Meningo evaluations) G6PD biosensor implementation HS-RDT HRP2 impact studies Innovation Platform Malaria and Fever programme management Malaria specimen bank P. vivax malaria - serology tests POC hematology PvSTATEM: digital tool for PvSeroTAT Temperature stability Typhoid diagnostic Vital signs triage toolkit Medical Affairs (EXPENSES $3,342,484) Billing of specimen dstribution Biobanking Development Clinical Affairs general management Clinical Trial unit general management Clinical-Regulatory-QMS COVID-19 (CTU) Diagnostics center of excellence Medical Affairs general management Medical Affairs portfolio management Program coordination and supervision Regulatory unit general management Specimen bank unit general management Neglected Tropical Diseases (EXPENSES $5,142,868) BU LAMP BU RDT development Chagas disease RDT development CUIDA Chagas Evaluation of onchocerciasis diagnostics Evaluation of RDTs for chronic Chagas disease HAT (sleeping sickness) elimination HAT elimination (Angola) HAT elimination (Chad) HAT elimination (DRC) HAT elimination (Guinea) HAT elimination (South Sudan) HAT elimination (Uganda) HAT Kenya HAT RDT development NTD biobanking collection in Ghana NTD programme management Schistosomiasis CAA RDT development Visceral leishmaniasis Ag RDT development Visceral leishmaniasis elimination Non-Communicable Diseases (EXPENSES $1,975,355) ACCEDE: Access to CGMs for Equity in Diabetes Mgt Access to Cardiometabolic Management Access to Glucose Measurement Through DxConnect Diabetes Management Education Diabetes Quality Assurance Evidences Digital Education for Pharmacists - Mclinica HbA1c POC h2h Comparison NCD Programme Management New Tech for Diabetes & Cardiometabolic Conditions Pandemic Threats (EXPENSES $7,439,585) AgRDT Demonstration study in Botswana COVID-19 Eval Antigen RDTs COVID-19 external quality assessment molecular COVID-19 Mobile Labs COVID-19 Surveillance data digital tool-kit COVID-19 test and treat Diagnostic Network Optimization OB surveillance DXOD: Diagnostics for outbreak diseases Taskforce Evaluation of COVID-19 Molecular POC tests External Quality Assessment CV Antigen Testing G7-G20 Engagement Independent Evaluation of Ebola RDTs Marburg RDT product development OB Lassa Fever Response OB Lassa Fever Response-Dissemination and training OB preparedness and response in West Africa Pandemic Threats programme management PATH/WHO/FIND COVID-19 diagnostic benchmarking PT market assessment and landscape Test evaluation network for OB disease diagnostics Yellow Fever RDT R&D a”

“In each region, find conducted the following program services - laboratory strengthening evaluation work.”

“Due to the high volume of organizations that were provided assistance from find during 2023, it would be difficult for find to list each organizations and grant amount individually on schedule f, part ii. Therefore, find has listed the total amount of assistance provided for region in 2023.”

“The organization's telephone number is +41 (22) 710 0590.”